This is a ready-to-use protocol for replication-competent retrovirus or lentivirus (RCR/RCL) testing across the vector and cell-therapy manufacturing lifecycle, including the patient follow-up dimension. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it. This is general guidance to adapt, not legal or regulatory advice.
Approval page (execute only after all signatures)
| Field | Entry |
|---|---|
| Protocol title | RCR/RCL Testing and Escalation for <<FILL: PRODUCT / VECTOR TYPE>> |
| Protocol number | <<FILL: PROT-ID>> |
| Version | <<FILL>> |
| Effective date | <<FILL>> |
| Vector type | <<FILL: lentiviral / gammaretroviral>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Process development / QC virology) | <<FILL>> | ||
| Biosafety officer | <<FILL>> | ||
| Quality Assurance (approver) | <<FILL>> | ||
| Pharmacovigilance lead | <<FILL>> |
1. Objective
To detect, at every point the risk arises, whether a replication-competent retrovirus or lentivirus has been generated during vector production or transduction, and to define the escalation and reporting path for any positive or inconclusive result, per CBER’s RCR testing guidance and ICH Q5A(R2).
2. Scope
In scope: RCR/RCL testing at vector production (end-of-production cells and supernatant), at the transduced cell product where applicable per risk assessment, and through long-term patient follow-up for <<FILL: PRODUCT>>. Out of scope: general adventitious agent testing of raw materials and cell banks, which is governed separately.
3. Testing points and methods
| Testing point | Material tested | Method | Frequency |
|---|---|---|---|
| Vector lot release | End-of-production cells | <<FILL: extended co-culture / PERT / qPCR assay>> | Every vector lot |
| Vector lot release | Vector supernatant | <<FILL>> | Every vector lot |
| Transduced cell product | <<FILL: per risk assessment>> | <<FILL>> | <<FILL>> |
| Patient follow-up | <<FILL: peripheral blood at defined intervals>> | <<FILL: PCR for vector sequences / replication markers>> | <<FILL: per long-term follow-up plan, up to 15 years for integrating vectors>> |
4. Responsibilities
| Role | Responsibility |
|---|---|
| QC virology | Executes assays, reports results, flags any positive or inconclusive result immediately |
| Biosafety officer | Owns containment response if a positive result implicates active manufacturing material |
| QA | Confirms testing occurred at every required point before disposition; owns the escalation record |
| Pharmacovigilance | Owns long-term follow-up reporting and any required health-authority notification |
| Regulatory affairs | Files any required expedited report |
5. Test cases
| TC ID | Testing point | Material | Method | Result | Interpretation |
|---|---|---|---|---|---|
| TC-01 | Vector lot release | End-of-production cells | <<FILL>> | <<FILL>> | <<FILL: negative/positive/inconclusive>> |
| TC-02 | Vector lot release | Supernatant | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-03 | Transduced product | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
6. Acceptance criteria
- Every required testing point for the product’s vector type is completed before the corresponding disposition decision (vector lot release, product release, or follow-up visit close-out).
- A negative result at every required point is required for standard vector lot release; a positive or inconclusive result triggers section 7 before any release proceeds.
- Long-term follow-up testing occurs at the defined intervals for the full committed duration.
7. Positive or inconclusive result: escalation path
- Immediate hold. QC virology notifies QA and the biosafety officer the same working day; the affected vector lot or product batch is placed on hold, not released or administered.
- Confirmatory testing. Repeat or orthogonal testing is performed per
<<FILL: confirmatory method>>before any conclusion is drawn from a single result. - Biosafety and manufacturing impact assessment. If confirmed, assess whether other lots manufactured on the same equipment or campaign could be implicated; the biosafety officer leads containment review.
- Clinical and pharmacovigilance notification. If the affected material was already administered, or a patient follow-up sample confirms a positive result, Pharmacovigilance notifies the treating physician and files any required expedited safety report per
<<FILL: applicable reporting timeline>>. - Health authority notification. Regulatory affairs determines and executes any required notification per
<<FILL: applicable jurisdiction and timeline>>. - Root cause and CAPA. A deviation/investigation is opened per
<<FILL: SOP-ID for deviations>>to determine cause and corrective action before manufacturing resumes.
8. Long-term follow-up plan summary
State the committed follow-up duration and schedule for integrating-vector products: <<FILL: e.g. up to 15 years, per the applicable FDA long-term follow-up guidance, with testing at defined intervals>>. Reference the full long-term follow-up protocol: <<FILL: reference>>.
9. References
FDA/CBER Guidance, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up (2020). ICH Q5A(R2), Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (2023 revision). FDA long-term follow-up guidance for gene therapy products (confirm current version and title).
Confirm the current version and title of each reference before issue.
10. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen (excerpt)
Illustrative lentiviral vector lot release testing.
| TC ID | Testing point | Material | Method | Result | Interpretation |
|---|---|---|---|---|---|
| TC-01 | Vector lot release | End-of-production cells | Extended co-culture with permissive indicator cell line | No cytopathic effect; RT-negative at endpoint | Negative |
| TC-02 | Vector lot release | Supernatant | qPCR for vector sequences in indicator cell amplification | No amplification above assay threshold | Negative |
Disposition: both testing points negative; vector lot proceeds to release per the standard disposition path. No escalation required.
Common inspection findings this protocol prevents
- RCR/RCL testing performed at only one point (e.g., vector release) with no testing on the transduced product or a documented risk-based rationale for skipping it.
- A positive or inconclusive result handled informally with no defined hold, confirmatory testing, or escalation record.
- Long-term follow-up testing lapsing after early visits with no documented tracking of the committed schedule.
- No defined biosafety containment response if a positive result is confirmed.
How to adapt this protocol
- Set your vector type, testing points, and methods from your own process and risk assessment.
- Confirm your long-term follow-up commitment duration against your current IND/BLA correspondence and the applicable FDA guidance.
- Point every escalation step to your real deviation, pharmacovigilance, and regulatory reporting procedures.
- Confirm every regulation in section 9 against the current published version before issue.